Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Cytosorbents (CTSO) Cost of Revenue (2016 - 2025)

Cytosorbents (CTSO) has disclosed Cost of Revenue for 14 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 16.03% year-over-year to $2.8 million, compared with a TTM value of $10.8 million through Sep 2025, down 27.93%, and an annual FY2024 reading of $10.5 million, down 25.0% over the prior year.
  • Cost of Revenue was $2.8 million for Q3 2025 at Cytosorbents, up from $2.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $7.2 million in Q4 2023 and bottomed at -$9.9 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $2.2 million, with a median of $2.7 million recorded in 2024.
  • The sharpest move saw Cost of Revenue plummeted 415.68% in 2022, then skyrocketed 649.24% in 2024.
  • Year by year, Cost of Revenue stood at $3.1 million in 2021, then tumbled by 415.68% to -$9.9 million in 2022, then soared by 172.75% to $7.2 million in 2023, then plummeted by 62.96% to $2.7 million in 2024, then rose by 6.12% to $2.8 million in 2025.
  • Business Quant data shows Cost of Revenue for CTSO at $2.8 million in Q3 2025, $2.8 million in Q2 2025, and $2.5 million in Q1 2025.